Browse ORAI1

Summary
SymbolORAI1
NameORAI calcium release-activated calcium modulator 1
Aliases FLJ14466; CRACM1; calcium release-activated calcium modulator 1; TMEM142A; transmembrane protein 142A; IMD9; ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein Note=Isoform beta is more mobile in the plasma membrane (PubMed:23307288). Colocalizes with STIM1 at the cell membrane (PubMed:27185316).
Domain PF07856 Mediator of CRAC channel activity
Function

Ca(2+) release-activated Ca(2+) (CRAC) channel subunit which mediates Ca(2+) influx following depletion of intracellular Ca(2+) stores and channel activation by the Ca(2+) sensor, STIM1 (PubMed:16582901, PubMed:16645049, PubMed:16733527, PubMed:16766533, PubMed:16807233, PubMed:19249086, PubMed:23307288, PubMed:24351972, PubMed:24591628, PubMed:28219928). CRAC channels are the main pathway for Ca(2+) influx in T-cells and promote the immune response to pathogens by activating the transcription factor NFAT (PubMed:16582901).

> Gene Ontology
 
Biological Process GO:0002115 store-operated calcium entry
GO:0002250 adaptive immune response
GO:0006816 calcium ion transport
GO:0010959 regulation of metal ion transport
GO:0043270 positive regulation of ion transport
GO:0051924 regulation of calcium ion transport
GO:0051928 positive regulation of calcium ion transport
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0072511 divalent inorganic cation transport
Molecular Function GO:0005216 ion channel activity
GO:0005261 cation channel activity
GO:0005262 calcium channel activity
GO:0005516 calmodulin binding
GO:0015085 calcium ion transmembrane transporter activity
GO:0015267 channel activity
GO:0015279 store-operated calcium channel activity
GO:0022803 passive transmembrane transporter activity
GO:0022838 substrate-specific channel activity
GO:0046873 metal ion transmembrane transporter activity
GO:0072509 divalent inorganic cation transmembrane transporter activity
Cellular Component GO:0005776 autophagosome
> KEGG and Reactome Pathway
 
KEGG hsa04020 Calcium signaling pathway
hsa04024 cAMP signaling pathway
hsa04611 Platelet activation
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-983695: Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
R-HSA-5576891: Cardiac conduction
R-HSA-139853: Elevation of cytosolic Ca2+ levels
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-5578775: Ion homeostasis
R-HSA-397014: Muscle contraction
R-HSA-418360: Platelet calcium homeostasis
R-HSA-418346: Platelet homeostasis
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
Summary
SymbolORAI1
NameORAI calcium release-activated calcium modulator 1
Aliases FLJ14466; CRACM1; calcium release-activated calcium modulator 1; TMEM142A; transmembrane protein 142A; IMD9; ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ORAI1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ORAI1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23922331Melanoma; Colon CarcinomaPromote immunityPatients with loss-of-function mutations in the CRAC channel genes ORAI1 or STIM1 are immunodeficient and are prone to develop virus-associated tumours. Using conditional knock out mice lacking STIM1 and its homologue STIM2, we find that SOCE in CD8(+) T cells is required to prevent the engraftment of melanoma and colon carcinoma cells and to control tumour growth.
Summary
SymbolORAI1
NameORAI calcium release-activated calcium modulator 1
Aliases FLJ14466; CRACM1; calcium release-activated calcium modulator 1; TMEM142A; transmembrane protein 142A; IMD9; ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ORAI1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolORAI1
NameORAI calcium release-activated calcium modulator 1
Aliases FLJ14466; CRACM1; calcium release-activated calcium modulator 1; TMEM142A; transmembrane protein 142A; IMD9; ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ORAI1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1340.7
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4440.85
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0980.952
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3190.427
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0820.951
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8310.642
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1610.637
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0110.993
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2740.844
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.060.463
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ORAI1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolORAI1
NameORAI calcium release-activated calcium modulator 1
Aliases FLJ14466; CRACM1; calcium release-activated calcium modulator 1; TMEM142A; transmembrane protein 142A; IMD9; ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ORAI1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolORAI1
NameORAI calcium release-activated calcium modulator 1
Aliases FLJ14466; CRACM1; calcium release-activated calcium modulator 1; TMEM142A; transmembrane protein 142A; IMD9; ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ORAI1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ORAI1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolORAI1
NameORAI calcium release-activated calcium modulator 1
Aliases FLJ14466; CRACM1; calcium release-activated calcium modulator 1; TMEM142A; transmembrane protein 142A; IMD9; ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ORAI1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolORAI1
NameORAI calcium release-activated calcium modulator 1
Aliases FLJ14466; CRACM1; calcium release-activated calcium modulator 1; TMEM142A; transmembrane protein 142A; IMD9; ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ORAI1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolORAI1
NameORAI calcium release-activated calcium modulator 1
Aliases FLJ14466; CRACM1; calcium release-activated calcium modulator 1; TMEM142A; transmembrane protein 142A; IMD9; ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ORAI1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolORAI1
NameORAI calcium release-activated calcium modulator 1
Aliases FLJ14466; CRACM1; calcium release-activated calcium modulator 1; TMEM142A; transmembrane protein 142A; IMD9; ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ORAI1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.